CYP2C19 and myocardial infarction: For CYP2C19, the primary endpoint, defined as the composite of myocardial infarction and death, was significantly higher in the poor metabolizer group than in the other group (PM vs NM or IM; 8.7% vs. 4.4%; Figure 1).